Radiotherapy News and Research RSS Feed - Radiotherapy News and Research

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).
Positive pre-clinical study data of Lamellar Biomedical's Visco-ease published in Supportive Care Journal

Positive pre-clinical study data of Lamellar Biomedical's Visco-ease published in Supportive Care Journal

Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical devices and pharmaceuticals, based on Lamellasome™ technology, is pleased to announce the publication of a paper in the Supportive Care in Cancer Journal. [More]
Proton beam therapy safe for treating childhood brain cancer medulloblastoma

Proton beam therapy safe for treating childhood brain cancer medulloblastoma

Proton beam therapy--a more precise form of radiotherapy--to treat the childhood brain cancer medulloblastoma appears to be as safe as conventional radiotherapy with similar survival rates, according to new research published in The Lancet Oncology journal today. [More]
Research points to potential use of radiotherapy in treating systemic cancer

Research points to potential use of radiotherapy in treating systemic cancer

An international team of researchers lead by the University of Granada has proven that mesenchymal stem cells (MSC) may be used as enhancer agents of local and systemic effects of radiotherapy, that is to say, those which affect the irradiated tumour and tumour cells located at a certain distance of the irradiated ones. [More]
Proton radiotherapy as effective as standard photon therapy in treating pediatric brain tumor

Proton radiotherapy as effective as standard photon therapy in treating pediatric brain tumor

The use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders, according to a study receiving online publication in Lancet Oncology. [More]
Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others. [More]
Overall EU cancer, leukaemia mortality rates to fall in 2016

Overall EU cancer, leukaemia mortality rates to fall in 2016

Total cancer-related mortality rates for men and women in the European Union will decline in 2016, say researchers who predict falls in death rates from most neoplasms, including leukaemia. [More]
Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

While there are a range of reports that different foods and food groups can increase or decrease your risk of cancer, these associations are very difficult to scientifically verify. [More]
Positive bosutinib response for elderly blast phase CML patient

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients. [More]
NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

According to recently published Pharmaion report, "Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020", the non-small cell lung cancer (NSCLC) treatments market in Europe is anticipated to cross US$ 3 billion by 2019. [More]
UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

UM SOM selected to work with BARDA to develop radiologic and nuclear countermeasures

University of Maryland School of Medicine Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority, for its Radiation Nuclear Animal Model Development program. [More]
Common painkiller diclofenac has significant anti-cancer properties

Common painkiller diclofenac has significant anti-cancer properties

Diclofenac, a common painkiller, has significant anti-cancer properties, according to researchers from the Repurposing Drugs in Oncology project. [More]
Does cancer affect memory? An interview with Associate Professor Janette Vardy

Does cancer affect memory? An interview with Associate Professor Janette Vardy

The study evaluated cognitive function in patients with colorectal cancer. It characterized the incidence and severity of cognitive impairment in people with colorectal cancer (CRC) compared to healthy controls. [More]
Statins could be effective against metastatic small cell lung cancer

Statins could be effective against metastatic small cell lung cancer

In a recent study, researchers at Cancer Treatment Centers of America at Western Regional Medical Center (Western), in collaboration with international colleagues, found that statins could be an effective therapeutic against metastatic small cell lung cancer (SCLC). [More]
NIH-funded clinical study examines new method for sparing healthy lung tissue during radiotherapy

NIH-funded clinical study examines new method for sparing healthy lung tissue during radiotherapy

A newly NIH funded clinical trial (NCT02528942) by University of Colorado Cancer Center investigators and collaborators at Beaumont Health in Michigan and the University of Texas Medical Branch is evaluating a new method for pinpointing and sparing healthy lung tissue during lung cancer radiotherapy. [More]
Exercise training could be a new treatment for prostate cancer

Exercise training could be a new treatment for prostate cancer

A newly-launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer. [More]
Radiation therapy lowers risk of cancer recurrence in pancreatic cancer surgery patients

Radiation therapy lowers risk of cancer recurrence in pancreatic cancer surgery patients

Radiation therapy was associated with a lower risk of cancer recurrence in pancreatic cancer surgery patients, making it, like chemotherapy, an important addition to treatment, Mayo Clinic research found. [More]
Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer announced today that new research findings on Xofigo (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place January 7 – 9 in San Francisco. [More]
New study reveals why some vestibular schwannomas cause hearing loss

New study reveals why some vestibular schwannomas cause hearing loss

A new study at Massachusetts Eye and Ear showed that in some cases of vestibular schwannoma, a sometimes-lethal tumor often associated with neurofibromatosis 2 (NF2), secretions from the tumor contain toxic molecules that damage the inner ear. [More]
Family members of CUP patients at higher risk of developing CUP themselves

Family members of CUP patients at higher risk of developing CUP themselves

Cancer usually begins in one location and then spreads, but in 3 percent to 5 percent of cancer patients, the tissue where a cancer begins is unknown. In these individuals a cancer diagnosis is made because it has metastasized to other sites. Patients with these so-called "cancers of unknown primary," or CUP, have a very poor prognosis, with a median survival of three months. [More]
Multiple small doses of targeted radiation therapy more effective at destroying pituitary gland tumors

Multiple small doses of targeted radiation therapy more effective at destroying pituitary gland tumors

A recent patient study at Houston Methodist Hospital proved that multiple small doses of highly focused radiation therapy is safer and more effective than a single larger dose of radiation at destroying pituitary gland tumors. [More]
Advertisement
Advertisement